Summit Therapeutics SMMT Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's proceeds from issuance of shares under incentive and share based compensation plans including stock options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
- Summit Therapeutics (SMMT) reported proceeds from issuance of shares under incentive and share based compensation plans including stock options of $3.8M in Q1 2026.
- How has Summit Therapeutics's proceeds from issuance of shares under incentive and share based compensation plans including stock options changed year-over-year?
- Summit Therapeutics's proceeds from issuance of shares under incentive and share based compensation plans including stock options increased by 88.1% year-over-year, from $2.02M to $3.8M.
- What is the long-term trend for Summit Therapeutics's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
- Over 3 years (2022 to 2025), Summit Therapeutics's proceeds from issuance of shares under incentive and share based compensation plans including stock options has grown at a 142.0% compound annual growth rate (CAGR), from $399K to $5.65M.